Tevogen Bio (NASDAQ:TVGN) Cut to “Strong Sell” at Wall Street Zen

Tevogen Bio (NASDAQ:TVGN) was downgraded by equities researchers at Wall Street Zen to a “strong sell” rating in a research report issued to clients and investors on Saturday.

Other analysts have also recently issued reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Tevogen Bio in a research note on Wednesday, January 21st. D. Boral Capital lowered Tevogen Bio from a “buy” rating to a “hold” rating in a research report on Wednesday, March 4th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $100.00.

Tevogen Bio Stock Performance

Shares of TVGN stock opened at $5.22 on Friday. The firm has a market capitalization of $20.72 million, a price-to-earnings ratio of -0.55 and a beta of -0.76. Tevogen Bio has a one year low of $4.89 and a one year high of $75.50. The company has a 50 day moving average price of $12.65 and a 200 day moving average price of $23.25.

Institutional Investors Weigh In On Tevogen Bio

Large investors have recently added to or reduced their stakes in the company. Bridgeway Capital Management LLC increased its stake in Tevogen Bio by 66.7% during the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after buying an additional 33,000 shares during the period. Deutsche Bank AG boosted its position in Tevogen Bio by 304.1% in the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after buying an additional 130,738 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in Tevogen Bio by 126.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock valued at $91,000 after buying an additional 152,572 shares during the last quarter.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.